EA037547B1 - Способ активации хелперных т-клеток - Google Patents

Способ активации хелперных т-клеток Download PDF

Info

Publication number: EA037547B1
Authority: EA; Eurasian Patent Office
Prior art keywords: hla; molecules; drb1; molecule; cells
Prior art date: 2010-10-05

Application number

EA201390509A

Other languages

English (en)

Russian (ru)

Other versions

EA201390509A1 (ru

Inventor

Харуо Сугияма

Синдзи Сого

Масайоси Сато

Рюки Китамото

Йосихиро Гото

Original Assignee

Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-05

Filing date

2011-10-04

Publication date

2021-04-12

2011-10-04 Application filed by Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. filed Critical Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк.

2013-08-30 Publication of EA201390509A1 publication Critical patent/EA201390509A1/ru

2021-04-12 Publication of EA037547B1 publication Critical patent/EA037547B1/ru

Links

210000002443 helper t lymphocyte Anatomy 0.000 title claims abstract description 89
238000000034 method Methods 0.000 title claims abstract description 73
230000003213 activating effect Effects 0.000 title claims abstract description 35
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 232
101150084041 WT1 gene Proteins 0.000 claims abstract description 149
108700020467 WT1 Proteins 0.000 claims abstract description 148
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 65
210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 57
102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims abstract description 56
108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims abstract description 56
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims description 196
108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 196
210000004027 cell Anatomy 0.000 claims description 100
102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 claims description 80
108010045483 HLA-DPB1 antigen Proteins 0.000 claims description 80
206010028980 Neoplasm Diseases 0.000 claims description 56
201000011510 cancer Diseases 0.000 claims description 47
108010053362 HLA-DRB1*04:06 antigen Proteins 0.000 claims description 43
102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims description 40
102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 claims description 40
108010061311 HLA-DRB3 Chains Proteins 0.000 claims description 40
108010040960 HLA-DRB4 Chains Proteins 0.000 claims description 40
108091033319 polynucleotide Proteins 0.000 claims description 39
102000040430 polynucleotide Human genes 0.000 claims description 39
239000002157 polynucleotide Substances 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 34
125000003275 alpha amino acid group Chemical group 0.000 claims description 33
101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims description 26
102100038823 RNA-binding protein 45 Human genes 0.000 claims description 26
239000013604 expression vector Substances 0.000 claims description 26
101100117565 Oryza sativa subsp. japonica DRB4 gene Proteins 0.000 claims description 23
230000027455 binding Effects 0.000 claims description 23
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 20
102000043131 MHC class II family Human genes 0.000 claims description 19
108091054438 MHC class II family Proteins 0.000 claims description 19
230000000890 antigenic effect Effects 0.000 claims description 18
102000004196 processed proteins & peptides Human genes 0.000 claims description 18
230000004913 activation Effects 0.000 claims description 16
108090000695 Cytokines Proteins 0.000 claims description 11
102000004127 Cytokines Human genes 0.000 claims description 11
PFBPIHUEFUNOIS-DVQPEGLTSA-N (2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,6-diaminohexanoyl]amino]pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid Chemical compound CSCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(O)=O PFBPIHUEFUNOIS-DVQPEGLTSA-N 0.000 claims description 10
230000004936 stimulating effect Effects 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
229920001184 polypeptide Polymers 0.000 claims description 2
102100022748 Wilms tumor protein Human genes 0.000 claims 25
101710127857 Wilms tumor protein Proteins 0.000 claims 1
102000040856 WT1 Human genes 0.000 abstract description 124
239000000427 antigen Substances 0.000 abstract description 5
108091007433 antigens Proteins 0.000 abstract description 5
102000036639 antigens Human genes 0.000 abstract description 5
108010074328 Interferon-gamma Proteins 0.000 description 52
102100037850 Interferon gamma Human genes 0.000 description 50
210000001744 T-lymphocyte Anatomy 0.000 description 44
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 38
102210010945 HLA-DRB1*0901 Human genes 0.000 description 36
108010029657 HLA-DRB1*04:01 antigen Proteins 0.000 description 34
108010024996 HLA-DRB1*04:05 antigen Proteins 0.000 description 28
230000006698 induction Effects 0.000 description 27
108090000623 proteins and genes Proteins 0.000 description 25
108010076599 HLA-DPB1*09:01 antigen Proteins 0.000 description 23
108700028369 Alleles Proteins 0.000 description 22
108010029618 HLA-DPB1*05:01 antigen Proteins 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 19
230000000638 stimulation Effects 0.000 description 18
101150034979 DRB3 gene Proteins 0.000 description 17
101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 17
239000002904 solvent Substances 0.000 description 15
230000003834 intracellular effect Effects 0.000 description 14
239000013598 vector Substances 0.000 description 13
239000006228 supernatant Substances 0.000 description 11
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 10
230000002265 prevention Effects 0.000 description 10
238000002965 ELISA Methods 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 9
239000000126 substance Substances 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
239000002609 medium Substances 0.000 description 8
108010058597 HLA-DR Antigens Proteins 0.000 description 7
102000006354 HLA-DR Antigens Human genes 0.000 description 7
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 7
239000002671 adjuvant Substances 0.000 description 7
239000000872 buffer Substances 0.000 description 7
230000014759 maintenance of location Effects 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
230000003394 haemopoietic effect Effects 0.000 description 6
108010002350 Interleukin-2 Proteins 0.000 description 5
206010035226 Plasma cell myeloma Diseases 0.000 description 5
239000012531 culture fluid Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
239000012530 fluid Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000005259 measurement Methods 0.000 description 5
206010005003 Bladder cancer Diseases 0.000 description 4
206010006187 Breast cancer Diseases 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
108010010378 HLA-DP Antigens Proteins 0.000 description 4
102000015789 HLA-DP Antigens Human genes 0.000 description 4
108010002586 Interleukin-7 Proteins 0.000 description 4
206010058467 Lung neoplasm malignant Diseases 0.000 description 4
206010025323 Lymphomas Diseases 0.000 description 4
102000043129 MHC class I family Human genes 0.000 description 4
108091054437 MHC class I family Proteins 0.000 description 4
208000034578 Multiple myelomas Diseases 0.000 description 4
201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 4
206010033128 Ovarian cancer Diseases 0.000 description 4
206010061535 Ovarian neoplasm Diseases 0.000 description 4
206010060862 Prostate cancer Diseases 0.000 description 4
208000000236 Prostatic Neoplasms Diseases 0.000 description 4
208000000453 Skin Neoplasms Diseases 0.000 description 4
208000005718 Stomach Neoplasms Diseases 0.000 description 4
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
208000002495 Uterine Neoplasms Diseases 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000007710 freezing Methods 0.000 description 4
230000008014 freezing Effects 0.000 description 4
206010017758 gastric cancer Diseases 0.000 description 4
201000003115 germ cell cancer Diseases 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
201000007270 liver cancer Diseases 0.000 description 4
208000014018 liver neoplasm Diseases 0.000 description 4
201000005202 lung cancer Diseases 0.000 description 4
208000020816 lung neoplasm Diseases 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
201000000849 skin cancer Diseases 0.000 description 4
201000011549 stomach cancer Diseases 0.000 description 4
230000036962 time dependent Effects 0.000 description 4
201000005112 urinary bladder cancer Diseases 0.000 description 4
206010046766 uterine cancer Diseases 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
210000004443 dendritic cell Anatomy 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000006167 equilibration buffer Substances 0.000 description 3
-1 for example Proteins 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000000411 inducer Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000013642 negative control Substances 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
239000013641 positive control Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
108020004414 DNA Proteins 0.000 description 2
108010062347 HLA-DQ Antigens Proteins 0.000 description 2
108010046732 HLA-DR4 Antigen Proteins 0.000 description 2
108010075101 HLA-DRB1*14:01 antigen Proteins 0.000 description 2
101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
210000000447 Th1 cell Anatomy 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
238000002659 cell therapy Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
229960003130 interferon gamma Drugs 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
239000000178 monomer Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
206010003445 Ascites Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102100039111 FAD-linked sulfhydryl oxidase ALR Human genes 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
101000959079 Homo sapiens FAD-linked sulfhydryl oxidase ALR Proteins 0.000 description 1
101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
108010083312 T-Cell Antigen Receptor-CD3 Complex Proteins 0.000 description 1
102100036407 Thioredoxin Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108700025700 Wilms Tumor Genes Proteins 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
229940022399 cancer vaccine Drugs 0.000 description 1
238000009566 cancer vaccine Methods 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000013024 dilution buffer Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
230000026030 halogenation Effects 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
210000000777 hematopoietic system Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
102000046004 human WT1 Human genes 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000010354 integration Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000012856 packing Methods 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
108060008226 thioredoxin Proteins 0.000 description 1
229940094937 thioredoxin Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
239000003643 water by type Substances 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Oncology (AREA)
Biophysics (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Developmental Biology & Embryology (AREA)

EA201390509A 2010-10-05 2011-10-04 Способ активации хелперных т-клеток EA037547B1 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2010225806		2010-10-05
PCT/JP2011/072874 WO2012046730A1 (ja)	2010-10-05	2011-10-04	ヘルパーｔ細胞の活性化方法

Publications (2)

Publication Number	Publication Date
EA201390509A1 EA201390509A1 (ru)	2013-08-30
EA037547B1 true EA037547B1 (ru)	2021-04-12

Family

ID=45927725

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EA201390509A EA037547B1 (ru)	2010-10-05	2011-10-04	Способ активации хелперных т-клеток

Country Status (20)

Country	Link
US (2)	US10654892B2 (ja)
EP (1)	EP2626418B8 (ja)
JP (3)	JP6134139B2 (ja)
KR (3)	KR102079480B1 (ja)
CN (2)	CN103298928B (ja)
AR (1)	AR083295A1 (ja)
AU (1)	AU2011313327B2 (ja)
BR (1)	BR112013008230A2 (ja)
CA (1)	CA2813557C (ja)
CO (1)	CO6710946A2 (ja)
EA (1)	EA037547B1 (ja)
ES (1)	ES2849187T3 (ja)
IL (2)	IL225536B (ja)
MX (2)	MX361299B (ja)
MY (1)	MY170306A (ja)
NZ (2)	NZ703560A (ja)
SG (3)	SG189287A1 (ja)
TW (2)	TWI608099B (ja)
WO (1)	WO2012046730A1 (ja)
ZA (1)	ZA201303056B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101213015B1 (ko)	2003-11-05	2012-12-26	인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드	Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
AU2006304573B2 (en)	2005-10-17	2012-05-24	Sloan Kettering Institute For Cancer Research	WT1 HLA class II-binding peptides and compositions and methods comprising same
EP3117836A1 (en)	2006-04-10	2017-01-18	Sloan Kettering Institute For Cancer Research	Immunogenic wt-1 peptides and uses thereof
CN104774910B (zh)	2007-02-27	2018-04-10	株式会社癌免疫研究所	活化辅助t细胞的方法以及用于该方法的组合物
AR076349A1 (es)	2009-04-23	2011-06-01	Int Inst Cancer Immunology Inc	Peptido auxiliar del antigeno del cancer
ES2849187T3 (es) *	2010-10-05	2021-08-16	Int Inst Cancer Immunology Inc	Método para activar células T auxiliares
JP6282598B2 (ja)	2012-01-13	2018-02-21	メモリアルスローンケタリングキャンサーセンター	免疫原性ｗｔ１ペプチド及びその使用方法
EP2896693A4 (en) *	2012-09-12	2016-10-12	Int Inst Cancer Immunology Inc	ANTIGEN SPECIFIC HELPER T CELL RECEPTOR GENES
JP6530192B2 (ja)	2012-12-17	2019-06-12	大塚製薬株式会社	ヘルパーｔ細胞の活性化方法
US10815273B2 (en)	2013-01-15	2020-10-27	Memorial Sloan Kettering Cancer Center	Immunogenic WT-1 peptides and methods of use thereof
CN116789792A (zh)	2013-01-15	2023-09-22	纪念斯隆凯特林癌症中心	免疫原性wt-1肽和其使用方法
DK2982681T3 (en)	2013-03-29	2018-12-10	Sumitomo Dainippon Pharma Co Ltd	WT1 ANTIGENPEPTIDKONJUGATVACCINE
EP3112378B1 (en) *	2014-02-26	2020-06-24	Tella, Inc.	Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
WO2016104486A1 (ja)	2014-12-25	2016-06-30	国立大学法人大阪大学	Ｔ細胞集団の改変方法
CN106565836B (zh) *	2015-10-10	2020-08-18	中国科学院广州生物医药与健康研究院	高亲和力的可溶性pdl-1分子
JP6994201B2 (ja)	2016-11-09	2022-02-21	国立大学法人大阪大学	Ｔ細胞集団の改変方法
US20200016255A1 (en) *	2016-11-30	2020-01-16	Sumitomo Dainippon Pharma Co., Ltd.	Wt1 helper peptides and combinations of wt1 helper peptide and conjugate of cancer antigen peptides
US20200368338A1 (en) *	2017-12-27	2020-11-26	Sumitomo Dainippon Pharma Co., Ltd.	Conjugate of wt1-derived peptides and composition comprising the same
CA3091099C (en) *	2018-02-15	2021-11-23	National University Corporation Asahikawa Medical University	Cancer antigen peptide
WO2020041501A1 (en) *	2018-08-22	2020-02-27	Fred Hutchinson Cancer Research Center	Immunotherapy targeting kras or her2 antigens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005045027A1 (ja) *	2003-11-05	2005-05-19	International Institute Of Cancer Immunology, Inc.	Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
WO2008105462A1 (ja) *	2007-02-27	2008-09-04	International Institute Of Cancer Immunology, Inc.	ヘルパーｔ細胞の活性化方法およびそのための組成物
WO2010123065A1 (ja) *	2009-04-23	2010-10-28	株式会社癌免疫研究所	癌抗原ヘルパーペプチド

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5726288A (en)	1989-11-13	1998-03-10	Massachusetts Institute Of Technology	Localization and characterization of the Wilms' tumor gene
CN1560078B (zh)	1998-07-31	2011-06-22	株式会社国际癌症免疫研究所	基于癌抑制基因wt1的产物的癌抗原
CA2349442C (en)	1998-09-30	2012-12-04	Corixa Corporation	Compositions and methods for wt1 specific immunotherapy
US7063854B1 (en)	1998-09-30	2006-06-20	Corixa Corporation	Composition and methods for WTI specific immunotherapy
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
CA2401070A1 (en)	2000-02-22	2001-08-30	Corixa Corporation	Compositions and methods for diagnosis and therapy of malignant mesothelioma
CA2440303C (en)	2001-03-22	2013-03-19	Haruo Sugiyama	Wt1 modified peptide
GB0108491D0 (en)	2001-04-04	2001-05-23	Gendaq Ltd	Engineering zinc fingers
WO2003002142A1 (en)	2001-06-29	2003-01-09	Chugai Seiyaku Kabushiki Kaisha	Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
JPWO2003028758A1 (ja)	2001-09-28	2005-01-13	治夫杉山	抗原特異的ｔ細胞の誘導方法
US8735357B2 (en)	2001-09-28	2014-05-27	International Institute Of Cancer Immunology, Inc.	Method of inducing antigen-specific T cells
ATE466084T1 (de)	2002-06-12	2010-05-15	Int Inst Cancer Immunology Inc	Hla-a24-restringiertes krebsantigenpeptid
ES2538486T3 (es)	2002-09-12	2015-06-22	International Institute Of Cancer Immunology, Inc.	Preparación de péptidos antigénicos contra el cáncer
ATE442378T1 (de)	2002-09-20	2009-09-15	Int Inst Cancer Immunology Inc	Substituierte wt1-peptide
US20060217297A1 (en)	2003-01-15	2006-09-28	Haruo Sugiyama	Dimerized peptide
ES2478446T3 (es)	2003-06-27	2014-07-22	International Institute Of Cancer Immunology, Inc.	Método de selección de pacientes candidatos para la vacuna contra WT1
SI1731605T1 (sl)	2004-03-31	2010-07-30	Internat Inst Of Cancer Immunolog Inc	Peptidi antigena karcinoma izvedeni iz WT1
US7608769B2 (en) *	2004-05-12	2009-10-27	First Act, Inc.	Packaged drum set
JP4719876B2 (ja)	2005-04-04	2011-07-06	国立大学法人愛媛大学	Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
AU2006304573B2 (en)	2005-10-17	2012-05-24	Sloan Kettering Institute For Cancer Research	WT1 HLA class II-binding peptides and compositions and methods comprising same
CN101336249A (zh)	2005-11-30	2008-12-31	株式会社癌免疫研究所	新型肽化合物
US7420880B2 (en)	2005-12-29	2008-09-02	Timex Group B.V.	Multimode electronic device with calibrating/setting mechanism
PL1988163T3 (pl)	2006-02-22	2012-11-30	Int Inst Cancer Immunology Inc	Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna
EP3117836A1 (en)	2006-04-10	2017-01-18	Sloan Kettering Institute For Cancer Research	Immunogenic wt-1 peptides and uses thereof
CA2886619A1 (en)	2006-12-28	2008-07-10	International Institute Of Cancer Immunology, Inc.	Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
EP3173480A3 (en)	2007-03-05	2017-08-16	International Institute of Cancer Immunology, Inc.	Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them
ES2849187T3 (es) *	2010-10-05	2021-08-16	Int Inst Cancer Immunology Inc	Método para activar células T auxiliares
JP6530192B2 (ja)	2012-12-17	2019-06-12	大塚製薬株式会社	ヘルパーｔ細胞の活性化方法

2011
- 2011-10-04 ES ES11830662T patent/ES2849187T3/es active Active
- 2011-10-04 KR KR1020197008457A patent/KR102079480B1/ko active IP Right Grant
- 2011-10-04 SG SG2013025622A patent/SG189287A1/en unknown
- 2011-10-04 CN CN201180058552.2A patent/CN103298928B/zh active Active
- 2011-10-04 NZ NZ703560A patent/NZ703560A/en unknown
- 2011-10-04 US US13/877,768 patent/US10654892B2/en active Active
- 2011-10-04 TW TW100135857A patent/TWI608099B/zh active
- 2011-10-04 AR ARP110103676A patent/AR083295A1/es unknown
- 2011-10-04 JP JP2012537718A patent/JP6134139B2/ja active Active
- 2011-10-04 AU AU2011313327A patent/AU2011313327B2/en active Active
- 2011-10-04 SG SG10201508252PA patent/SG10201508252PA/en unknown
- 2011-10-04 MY MYPI2013001197A patent/MY170306A/en unknown
- 2011-10-04 CN CN201610191489.4A patent/CN105802910A/zh active Pending
- 2011-10-04 WO PCT/JP2011/072874 patent/WO2012046730A1/ja active Application Filing
- 2011-10-04 SG SG10202108581TA patent/SG10202108581TA/en unknown
- 2011-10-04 BR BR112013008230A patent/BR112013008230A2/pt not_active Application Discontinuation
- 2011-10-04 KR KR1020207004213A patent/KR102171794B1/ko active IP Right Grant
- 2011-10-04 CA CA2813557A patent/CA2813557C/en active Active
- 2011-10-04 TW TW105107752A patent/TW201623616A/zh unknown
- 2011-10-04 EP EP11830662.0A patent/EP2626418B8/en active Active
- 2011-10-04 KR KR1020137011554A patent/KR20140009168A/ko not_active Application Discontinuation
- 2011-10-04 EA EA201390509A patent/EA037547B1/ru unknown
- 2011-10-04 MX MX2013003884A patent/MX361299B/es active IP Right Grant
- 2011-10-04 NZ NZ609460A patent/NZ609460A/en unknown
2013
- 2013-04-02 IL IL225536A patent/IL225536B/en not_active IP Right Cessation
- 2013-04-05 MX MX2018008436A patent/MX2018008436A/es unknown
- 2013-04-25 ZA ZA2013/03056A patent/ZA201303056B/en unknown
- 2013-05-03 CO CO13111246A patent/CO6710946A2/es unknown
2016
- 2016-05-03 IL IL245440A patent/IL245440A0/en unknown
- 2016-05-31 JP JP2016109398A patent/JP6298101B2/ja active Active
2017
- 2017-12-12 JP JP2017237964A patent/JP2018093870A/ja active Pending
2020
- 2020-03-31 US US16/835,761 patent/US20200354405A1/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005045027A1 (ja) *	2003-11-05	2005-05-19	International Institute Of Cancer Immunology, Inc.	Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
WO2008105462A1 (ja) *	2007-02-27	2008-09-04	International Institute Of Cancer Immunology, Inc.	ヘルパーｔ細胞の活性化方法およびそのための組成物
WO2010123065A1 (ja) *	2009-04-23	2010-10-28	株式会社癌免疫研究所	癌抗原ヘルパーペプチド

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FUJIKI, F., et al., "A WT1 Protein-derived, naturally processed 16 mer peptide, WT1322, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4+ T cells", Microbiol. Immunol., 2008, Vol.52, p.591-600 *
KNIGHTS, A.J., et al., "Prediction of an HLA-DR-binding peptide derived from Wilms' tumor 1 protein and demonstration of in vitro immunogenicity of WT1(1240138)-pulsed dendritic cells generated according to an optimized protocol", Cancer Immunol. Immunother., Vol.51, 2002, p.271-281 *
LEHE, C., et al., "The Wilms' Tumor antigen is a novel target for human CD4+ regulatory T cells: Implications for immunotherapy", Cancer Res., Vol.68, 2008, p.6350-6359 *
MAY, R.J., et al., "Peptide epitopes from the Wilms' Tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells" Clin Cancer Res., 2007, Vol.13, No.15, p.4547-4555 *
MULLER, L., et al., "Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells", Hematol.J., Vol. 4, 2003, p.57-66 *

Also Published As

Publication number	Publication date
KR102079480B1 (ko)	2020-02-19
EP2626418A4 (en)	2014-02-19
KR20140009168A (ko)	2014-01-22
IL225536A0 (en)	2013-06-27
TW201217525A (en)	2012-05-01
CN103298928A (zh)	2013-09-11
US10654892B2 (en)	2020-05-19
EP2626418B8 (en)	2021-03-24
BR112013008230A2 (pt)	2016-06-14
MY170306A (en)	2019-07-17
MX361299B (es)	2018-11-30
SG10202108581TA (en)	2021-09-29
KR102171794B1 (ko)	2020-10-29
JP6298101B2 (ja)	2018-03-20
SG10201508252PA (en)	2015-11-27
NZ703560A (en)	2016-11-25
EA201390509A1 (ru)	2013-08-30
JP6134139B2 (ja)	2017-05-24
CN103298928B (zh)	2016-04-20
WO2012046730A1 (ja)	2012-04-12
CA2813557C (en)	2021-05-04
IL245440A0 (en)	2016-06-30
EP2626418B1 (en)	2020-12-09
US20130266958A1 (en)	2013-10-10
CA2813557A1 (en)	2012-04-12
IL225536B (en)	2019-03-31
KR20200018738A (ko)	2020-02-19
JP2018093870A (ja)	2018-06-21
AR083295A1 (es)	2013-02-13
KR20190034359A (ko)	2019-04-01
ZA201303056B (en)	2013-12-23
EP2626418A1 (en)	2013-08-14
CO6710946A2 (es)	2013-07-15
JP2017006120A (ja)	2017-01-12
US20200354405A1 (en)	2020-11-12
JPWO2012046730A1 (ja)	2014-02-24
NZ609460A (en)	2015-07-31
MX2013003884A (es)	2013-07-05
AU2011313327A1 (en)	2013-05-02
TWI608099B (zh)	2017-12-11
SG189287A1 (en)	2013-05-31
ES2849187T3 (es)	2021-08-16
MX2018008436A (es)	2021-12-08
TW201623616A (zh)	2016-07-01
CN105802910A (zh)	2016-07-27
AU2011313327B2 (en)	2015-10-22

Publication	Publication Date	Title
US20200354405A1 (en)	2020-11-12	Method for activating helper t cell
KR101391561B1 (ko)	2014-05-02	Ｈｌａ-ａ*3303 구속성 ｗｔ1 펩티드, 및 그것을 포함하는 의약 조성물
JP6530192B2 (ja)	2019-06-12	ヘルパーｔ細胞の活性化方法
KR101598228B1 (ko)	2016-02-26	헬퍼 ｔ 세포의 활성화 방법 및 그를 위한 조성물
JPWO2016093243A1 (ja)	2017-11-02	腫瘍抗原ペプチド
WO2017086354A1 (ja)	2017-05-26	Ｈｌａ－ａ１１拘束性細胞傷害性ｔ細胞エピトープペプチド